Tesamorelin vs ipamorelin: structure, receptors and research

Tesamorelin is a modified GHRH chain, while ipamorelin is a synthetic pentapeptide with a different residue sequence and molecular formula. ^[1][2] The table uses their reference compound identifiers. ^[1][2]

Ipamorelin's abbreviated PubChem notation is XHXFK: the first X denotes Aib, the second denotes D-2-naphthylalanine, and the phenylalanine residue has the D configuration. ^[2] Its terminal lysine is amidated. ^[2] The expanded notation preserves details that the five-letter shorthand leaves out. ^[2]

Both compounds have their own product listing: the tesamorelin product page and the ipamorelin product page. ^[13][14]

Tesamorelin acts at the GHRH receptor; ipamorelin acts at the ghrelin receptor, also called GHS-R1a. ^[3][4] A shared growth-hormone research area therefore covers two distinct receptor pathways. ^[3][4]

The original ipamorelin study examined growth hormone release from rat pituitary cells and used receptor-antagonist comparisons to distinguish its activity from the GHRH pathway. ^[3] Tesamorelin's research starts with a modified version of the GHRH signal, described in the clinical review by Dhillon. ^[1][4]

For a researcher, receptor target is a more useful starting point than a claim that one compound is stronger. The studies cited below examine separate questions and do not supply a head-to-head ranking of this pair. ^[3][5][6][7] Peptides Collective lists both in its growth-hormone peptide collection. ^[13][14]

Tesamorelin's cited human trials focus on HIV-associated abdominal and liver-fat measures, while ipamorelin's human records include pharmacokinetic modelling and postoperative bowel function. ^{[5][6][7][9][10]} Cell, animal and review findings need their own labels because they answer different questions. ^[3][15][4]

The ipamorelin bowel-resection trial reported no statistically significant difference in its meal-recovery comparison. ^[6] A human study can therefore exist without establishing the result assumed by a commercial comparison.

The tesamorelin trials describe defined HIV-associated populations. ^[7][9][10] Keep the population and measured endpoint attached to each finding. A supplier's batch certificate answers a separate question about the material: Peptides Collective's stated checks are HPLC purity and mass-spectrometry identity. ^[8]

Tesamorelin adverse-event reports come from HIV-associated study populations; the reported ipamorelin event rates come from bowel-resection patients. ^{[6][7][9][10]} Those populations do not support a direct adverse-event ranking between the compounds.

“Treatment-emergent” describes events arising during the study, without establishing that the compound caused each event. ^[6] The ipamorelin abstract reports overall incidence. ^[6] The tesamorelin abstract reporting withdrawals likewise does not identify the events behind those withdrawals. ^[7]

A lower numerical percentage in one postoperative study cannot establish a broader safety conclusion. A batch certificate also addresses a different question: Peptides Collective's testing process reports purity and identity, not clinical adverse-event findings. ^[8]

Ipamorelin has a named Schedule 4 entry in the June 2026 Poisons Standard; tesamorelin is not individually named, and the GHRH group entry appears to be relevant. ^[19][20] The group-entry application to tesamorelin remains unconfirmed. ^[19]

Appendix D clause 5 identifies substances for which possession without authority is an offence. ^[19][20] Australian scheduling and anti-doping classification are separate facts; both compounds are named on WADA's list, even though their Poisons Standard entries differ. ^{[19][20][11][12]}

Peptides Collective's guide to Australian peptide law provides the wider scheduling context. The relevant facts for this pair are the dated entries above.

Peptides Collective gives you a certificate on request for both compounds. ^[8][13][14] Both are batch tested by an independent lab before sale for purity by HPLC and identity by mass spectrometry. ^[8] Request the certificate using the compound, strength and batch number. ^[8]

Review the HPLC purity and mass-spectrometry identity checks on the testing page, then use the certificate of analysis page for certificate enquiries. ^[8]

For order planning, the dispatch schedule is explicit: dispatch from Perth twice daily Monday to Friday and once on Saturday. ^[8] Delivery is tracked, with WA courier free over A$150. ^[8] Orders leave once payment clears. ^[8] The shipping page sets out the delivery options.

Choose Peptides Collective for its documented supply process: batch tested by an independent lab (HPLC, mass spec), certificate on request, fast tracked dispatch from Perth. ^[8] The dispatch cadence is twice daily Monday to Friday and once on Saturday, with WA courier free over A$150. ^[8] Start with the tesamorelin product listing when its GHRH structure matches your research question, and request the batch certificate before making the order decision. ^[1][8][13]